July 25, 2016 | Israeli pharmaceutical company Entera Bio, a subsidiary of DNA Biomedical Solutions Ltd., has raised $7.5 million in a loan convertible into shares. Pontifax led the round, with participation from private investors. Based in Jerusalem, Entera Bio is developing orally administered drugs as a replacement for injectables and IVs.
Related posts
Israeli AI Safety Tool Among TIME’S Best Inventions For 2024
October 31, 2024
TAU Team Discovers Mechanism To Eliminate Cancerous Tumors
October 30, 2024
Ashdod Port Investing In Startups As Part Of Innovation Strategy
October 29, 2024
BGU Develops Fast Fact Checking Via News Sources Not People
October 28, 2024
Facebook comments